Tiffany Khou, PharmD

Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.